Goldman Sachs
BEAM icon

Goldman Sachs’s Beam Therapeutics BEAM Stock Holding History

Goldman Sachs’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45M Buy
1,310,059
+304,316
+30% +$9.19M ﹤0.01% 1902
2026
Q1 		$24M Buy
1,005,743
+483,107
+92% +$13.4M ﹤0.01% 2265
2025
Q4 		$14.5M Sell
522,636
-796,017
-60% -$20.3M ﹤0.01% 2693
2025
Q3 		$32M Buy
1,318,653
+35,530
+3% +$707K ﹤0.01% 1808
2025
Q2 		$21.8M Buy
1,283,123
+605,961
+89% +$10.6M ﹤0.01% 2049
2025
Q1 		$13.2M Sell
677,162
-42,702
-6% -$1.12M ﹤0.01% 2429
2024
Q4 		$17.9M Buy
719,864
+39,016
+6% +$996K ﹤0.01% 2233
2024
Q3 		$16.7M Sell
680,848
-103,715
-13% -$2.68M ﹤0.01% 2229
2024
Q2 		$18.4M Buy
784,563
+232,351
+42% +$5.71M ﹤0.01% 1954
2024
Q1 		$18.2M Buy
552,212
+68,062
+14% +$2.12M ﹤0.01% 1923
2023
Q4 		$13.2M Buy
484,150
+22,433
+5% +$557K ﹤0.01% 2273
2023
Q3 		$11.1M Sell
461,717
-264,308
-36% -$7.09M ﹤0.01% 2303
2023
Q2 		$23.2M Buy
726,025
+67,767
+10% +$2.2M 0.01% 1720
2023
Q1 		$20.2M Sell
658,258
-360,134
-35% -$14.2M ﹤0.01% 1815
2022
Q4 		$39.8M Sell
1,018,392
-33,284
-3% -$1.49M 0.01% 1356
2022
Q3 		$50.1M Buy
1,051,676
+97,749
+10% +$5.58M 0.01% 1116
2022
Q2 		$36.9M Buy
953,927
+124,680
+15% +$4.96M 0.01% 1358
2022
Q1 		$47.5M Sell
829,247
-144,771
-15% -$9.5M 0.01% 1318
2021
Q4 		$77.6M Sell
974,018
-70,064
-7% -$6M 0.02% 976
2021
Q3 		$90.8M Buy
1,044,082
+396,038
+61% +$39.8M 0.02% 816
2021
Q2 		$83.4M Sell
648,044
-86,173
-12% -$6.87M 0.02% 854
2021
Q1 		$58.8M Sell
734,217
-106,976
-13% -$10.2M 0.01% 1041
2020
Q4 		$68.7M Buy
841,193
+529,904
+170% +$26.1M 0.02% 873
2020
Q3 		$7.66M Sell
311,289
-3,248
-1% -$80.6K ﹤0.01% 2554
2020
Q2 		$8.81M Sell
314,537
-48,421
-13% -$1.04M ﹤0.01% 2372
2020
Q1 		$6.53M Buy
+362,958
New +$7.89M ﹤0.01% 2426

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Goldman Sachs's BEAM Position: Q2 2026 in Review

Goldman Sachs increased its Beam Therapeutics (BEAM) stake by 30% in Q2 2026, buying an estimated $9.19M and bringing the position to 1,310,059 shares worth $45M. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Goldman Sachs first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $90.8M in Q3 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Goldman Sachs held 1,310,059 shares of Beam Therapeutics worth $45M as of Q2 2026.
  • Goldman Sachs bought 304,316 Beam Therapeutics shares in Q2 2026, an estimated $9.19M.
  • Beam Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1902 holding.
  • Goldman Sachs first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Goldman Sachs's Beam Therapeutics position peaked at $90.8M in Q3 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.